title: The primacy of clinical effectiveness for cost effectiveness analysis.
authors.forename: I P
authors.initials: IP
authors.lastname: Casserly
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
mesh_terms: D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000191:economics* / Q000401:mortality / Q000628:therapy; D003362:Cost-Benefit Analysis; D017985:Dalteparin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D013577:Syndrome; D013997:Time Factors
chemical_list: D005343:Fibrinolytic Agents; D017985:Dalteparin